Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 11/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19481519 | 0.88 | FAAH (0.77) | FAAHS1PR1S1PR3 | |
| SCHEMBL17309293 | 0.88 | FAAH (0.77) | FAAHS1PR1S1PR3 | |
| SCHEMBL17309390 | 0.81 | FAAH (0.78) | FAAHS1PR1S1PR3MEN1KMT2A | |
| SCHEMBL17309379 | 0.80 | FAAH (0.70) | FAAHS1PR1S1PR3MEN1KMT2A | |
| SCHEMBL17295530 | 0.80 | FAAH (0.67) | FAAHS1PR1S1PR3MEN1KMT2A | |
| SCHEMBL17295531 | 0.80 | FAAH (0.67) | FAAHS1PR1S1PR3MEN1KMT2A | |
| SCHEMBL19096218 | 0.79 | FAAH (0.58) | FAAHS1PR1S1PR3MEN1KMT2A | |
| SCHEMBL17295281 | 0.78 | FAAH (0.62) | FAAHS1PR1S1PR3MEN1KMT2A | |
| SCHEMBL17295279 | 0.78 | FAAH (0.62) | FAAHS1PR1S1PR3MEN1KMT2A | |
| SCHEMBL17309392 | 0.78 | FAAH (0.91) | FAAHS1PR1S1PR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148541-B1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIV BERN (CH) | 2020-09-02 | — | — | EP | disclosed |